Isoquinolinone compound, and preparation method and use therefor

Patent metadata

Field	Value
Publication number	US-2025170121-A1
Application number	US-202318841895-A
Country	US
Kind code	A1
Filing date	Mar 27, 2023
Priority date	Feb 28, 2022
Publication date	May 29, 2025
Grant date	—

Abstract

Provided are an isoquinolinone compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a prodrug molecule, and a mixture thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as an FABP4/FABP5 dual-targeting inhibitor. Related aryl carboxylic acid compounds can be used for preparing drugs for treating metabolic diseases (such as diabetes, insulin resistance, hyperlipidemia, and atherosclerosis), autoimmune diseases and cancers.

First claim

1 . An isoquinolinone compound represented by the general formula (I), a pharmaceutically acceptable salt, stereoisomer, prodrug molecule thereof or their mixture:

wherein,
R 1 is selected from the group consisting of substituted or unsubstituted phenyl, C 5 -C 12 aromatic heterocyclyl containing oxygen, nitrogen and/or sulfur, C 3 -C 8 cycloalkyl, and 4-7 membered heterocyclyl containing 1 to 3 heteroatoms of oxygen, nitrogen and/or sulfur; in the case where the R 1 group has a substituent, each substituent is independently selected from the group consisting of halogen, hydroxyl, hydroxymethyl, thiol, amino, cyano, nitro, carboxyl, ester group, trifluoromethyl, trifluoromethoxy, C 1 -C 6 straight-chain or branched-chain alkyl, C 1 -C 6 straight-chain or branched-chain haloalkyl, C 1 -C 6 straight-chain or branched-chain alkoxy, C 1 -C 6 straight-chain or branched-chain haloalkoxy, C 1 -C 6 straight-chain or branched-chain alkylcarbonyloxy, and C 1 -C 6 straight-chain or branched-chain hydroxyalkyl:
R 2 is selected from the group consisting of carboxyl, cyano, hydroxyl, sulfonyl hydroxide, sulfonamide group, amide group, tetrazole group, squaryl, phosphate group, hydroxamic acid group, and hydroxyisoxazole group:
R 3 is selected from the group consisting of substituted or unsubstituted phenyl: C 6 -C 12 aryl: benzyl: C 5 -C 7 aromatic heterocycle containing oxygen, nitrogen and sulfur: C 3 -C 14 cycloalkyl: and 4-8 membered heterocyclyl: in the case where the R 3 group has a substituent (i.e. “substituted”), each substituent is independently selected from the group consisting of halogen, hydroxyl, hydroxymethyl, thiol, amino, cyano, nitro, carboxyl, ester group, trifluoromethyl, trifluoromethoxy, C 1 -C 6 straight-chain alkyl or C 3 -C 6 branched-chain alkyl, C 1 -C 6 straight-chain haloalkyl or C 3 -C 6 branched-chain haloalkyl, C 1 -C 6 straight-chain alkoxy or C 3 -C 6 branched-chain alkoxy, and C 1 -C 6 straight-chain haloalkoxy:
R 4 to R 7 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, cyano, thiol, trifluoromethyl, trifluoromethoxy, nitro, amide group, sulfonamide group, C 1 -C 3 straight-chain or branched alkyl, and C 1 -C 3 straight-chain or branched-chain alkoxy:

2 . The isoquinolinone compound, the pharmaceutically acceptable salt, stereoisomer, prodrug molecule thereof or their mixture of claim 1 , wherein,
R 1 is selected from the group consisting of C 3 -C 8 cycloalkyl, 4-7 membered heterocyclyl containing 1 to 3 heteroatoms of oxygen, nitrogen and/or sulfur, and substituted or unsubstituted phenyl: in the case where the R 1 group has a substituent (i.e. “substituted”), each substituent is independently selected from the group consisting of halogen, hydroxyl, hydroxymethyl, thiol, amino, cyano, nitro, carboxyl, ester group, trifluoromethyl, trifluoromethoxy, C 1 -C 3 straight-chain or branched-chain alkyl, and C 1 -C 3 straight-chain or branched-chain alkoxy: R 2 is selected from the group consisting of carboxyl, sulfonyl hydroxide, sulfonamide group, amide group, tetrazole group, squaryl, and hydroxyisoxazole group: R 3 is selected from the group consisting of substituted or unsubstituted phenyl: C 5 -C 7 aromatic heterocycle containing oxygen, nitrogen and sulfur: C 3 -C 14 cycloalkyl; and 4-8 membered heterocyclyl: in the case where the R 3 group has a substituent (i.e. “substituted”), each substituent is independently selected from the group consisting of halogen, hydroxyl, hydroxymethyl, thiol, amino, cyano, nitro, carboxyl, ester group, trifluoromethyl, and trifluoromethoxy: R 4 to R 7 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, trifluoromethyl, trifluoromethoxy, nitro, and methoxy: preferably, R 2 is —COOH, R 3 is phenyl, substituted phenyl (e.g., chlorophenyl, fluorophenyl, methylphenyl, benzyl, trifluoromethylphenyl) or aromatic heterocyclyl, R 4 , R 6 and R 7 are independently hydrogen: further preferably, R 1 is selected from the group consisting of cyclohexyl, methylcyclohexyl, cyclopentyl, tetrahydropyranyl, cyclopropyl, cyclobutyl, cycloheptyl, chlorophenyl, piperidinyl and cyclopentyl: R 2 is carboxyl: R 3 is selected from the group consisting of phenyl, fluorophenyl, hydroxyphenyl, hydroxymethylphenyl, chlorofluorophenyl, trifluoromethylphenyl, dihydrobenzofuranyl, pyridinyl, and dimethylpyrazolyl; R 4 and R 7 are independently H or they are simultaneously H, R 5 is Cl, Br or methyl; and R 6 is H or Cl.

3 . The isoquinolinone compound, the pharmaceutically acceptable salt, stereoisomer, prodrug molecule thereof or their mixture of claim 1 , wherein the compound is selected from the group consisting of the following compounds:

4 . Use of the isoquinolinone compound, the pharmaceutically acceptable salt, stereoisomer, prodrug molecule thereof or their mixture of claim 1 in the preparation of a drug for preventing or treating FABP4/5-mediated diseases.

5 . Use of claim 5 , wherein, the FABP4/5-mediated diseases are metabolic diseases, cardiovascular and cerebrovascular diseases, inflammatory diseases, autoimmune diseases, organ fibrosis diseases, neurological damage diseases, secondary diseases caused by pathogen infection or tumors.

6 . Use of claim 5 , wherein, the metabolic disease is selected from one or more of insulin resistance, type 2 diabetes, atherosclerosis, hyperlipidemia and non-alcoholic fatty liver disease: the autoimmune disease is selected from one or more of psoriasis and rheumatoid arthritis; the acute inflammation is selected from one or more of sepsis, septicemia, acute kidney injury, acute lung injury, and acute liver injury: the cancer is selected from one or more of malignant melanoma, lung cancer, gastric cancer, breast cancer, colon cancer, bladder cancer, pancreatic cancer, lymphoma, leukemia, prostate cancer, ovarian cancer, liver cancer, and cervical cancer.

7 . A pharmaceutical composition, which contains a therapeutically effective amount of the isoquinolinone compound, the pharmaceutically acceptable salt, stereoisomer, prodrug molecule thereof or their mixture of any one of claims 1 to 3 .

8 . The pharmaceutical composition of claim 7 , wherein the isoquinolinone compound, the pharmaceutically acceptable salt, stereoisomer, prodrug molecule thereof or their mixture accounts for 20% to 99% of the total weight of the pharmaceutical composition.

9 . The pharmaceutical composition of claim 7 or 8 , wherein the composition further comprises one or more pharmaceutically acceptable carriers, odorants, flavoring agents, vehicles and/or diluents.

10 . Use of the pharmaceutical composition of any one of claims 7 to 9 in the preparation of a drug for preventing and treating FABP4/5-mediated diseases, wherein the diseases are metabolic diseases, cardiovascular and cerebrovascular diseases, inflammatory diseases, autoimmune diseases, organ fibrosis diseases, neurological damage diseases, secondary diseases caused by pathogen infection or tumors.

Assignees

• Univ Fudan
• Shanghai Inst Materia Medica Cas

Inventors

• Li Yingxia
• Wang Heyao
• He Yulong
• Li Shunyi

Classifications

• C07D413/14

  containing three or more hetero rings · CPC title

• C07D401/14

  containing three or more hetero rings · CPC title

• C07D401/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D217/24

  Oxygen atoms · CPC title

• C07D405/10

  linked by a carbon chain containing aromatic rings · CPC title